{"id":"W2947265946","doi":"10.1200/jco.2019.37.15_suppl.2507","title":"Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":192,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Nivolumab; Pharmacodynamics; Pharmacokinetics; Lymphoma; Gastroenterology; Oncology; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001719485,0.0001690258,0.001710883,0.0003212005,0.00001381183,0.000005094504,0.0001483052,0.00011273,0.0001270095],"category_scores_gemma":[0.0004194903,0.0000982823,0.0001239004,0.0004416497,0.0001525463,0.0001911328,0.00002164572,0.0004581566,0.000003562107],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000322216,"about_ca_system_score_gemma":0.001277658,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007033488,"about_ca_topic_score_gemma":0.0008092428,"domain_scores_codex":[0.9960943,0.0004023076,0.002526287,0.0002178861,0.0005300686,0.0002291187],"domain_scores_gemma":[0.9964011,0.0007345208,0.002150687,0.0002144002,0.000366838,0.0001324078],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.2339394,0.04667432,0.6239468,0.00007856126,0.000388811,0.0007117438,0.0007441139,0.00009788373,0.00007518802,0.000003620024,0.00009722819,0.09324224],"study_design_scores_gemma":[0.2194781,0.2326708,0.544947,0.0004914854,0.0001395391,0.00009353078,0.001352389,0.00008743888,0.00007039791,0.00001746385,0.0005559422,0.00009601072],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9979578,0.00008410881,0.00001245479,0.0003543607,0.0003627879,0.0009604185,0.000002551229,0.000003858819,0.0002616398],"genre_scores_gemma":[0.9987004,0.0001009929,0.0005863762,0.0004118468,0.00005016313,0.00001029571,0.000004257865,0.00002043458,0.0001151684],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1859964,"threshold_uncertainty_score":0.4007836,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06145907686833232,"score_gpt":0.4461295254891137,"score_spread":0.3846704486207814,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}